FDA Approves First Telehealth Option to Program Cochlear Implants Remotely

The U.S. Food and Drug Administration today approved a remote feature for follow-up programming sessions for the Nucleus Cochlear Implant System through a telemedicine platform. The remote programming feature is indicated for patients who have had six months of experience with their cochlear implant sound processor and are comfortable with the programming process.

To read the entire press release from the FDA, click here.